Keywords:
Performed at one institution, Cross-sectional study, Prospective, Cancer, Diagnostic procedure, Contrast agent-intravenous, MR, Breast
Authors:
N. M. E. M. Settein, S. Abdallah, M. abdel shaheed; Mansoura/EG
DOI:
10.26044/ecr2020/C-03252
Purpose
Immunohistochemical (IHC) markers, together with clinicopathological variables such as tumor size, tumor grade, nodal involvement, histologic type, and surgical margins, have been widely used for prognosis, prediction and treatment selection.(1)(2)
Correlating imaging phenotype with genomic information (often referred to as "radiogenomics") (3), in order to better understand genetic variability and the ability to predict prognosis or response to therapy, is a new field of research. (4)(5)
The 2011 St. Gallen panel supported the immunohistochemical determination of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) as useful markers for defining the subtypes.(6)(7)
The four major breast cancer subtypes include: Luminal A (ER and/or PR positive, HER2 negative), Luminal B (ER and/or PR positive, as well as HER2 positive), HER2 enriched (HER2 amplified, ER and PR negative) and Triple-negative (ER, PR, and HER2 negative). (8)
The purpose of our study to find out if there is a relationship between magnetic resonance imaging (MRI) morphology of malignant breast lesions and their immunohistochemical profile by correlating the morphological details to the type of tumor receptors within the lesions.